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Abstract
Background: Besides acting as definitive hosts for Echinococcus multilocularis, dogs can become infected by the
larval form of this parasite and thereby develop life-threatening alveolar echinococcosis (AE). Although AE is a
zoonotic disease, most therapeutic and diagnostic approaches have been developed for human patients. In dogs,
AE is typically diagnosed in the advanced stage of the disease when the parasitic mass has already caused abdominal
distension. At that stage, complete resection of the parasitic mass is often impossible, leaving a guarded prognosis for
the affected dogs. For humans, sensitive and specific diagnostic protocols relying on serology have been validated and
are now widely used. In contrast, sensitive and specific laboratory diagnostic tools that would enable early diagnosis of
canine AE are still lacking. The aim of the current study was to establish a serological protocol specifically adapted to
dogs.
Methods: We tested several native and recombinant antigens (EmVF, Em2, recEm95, recEm18) in in-house
ELISA, an in-house Western blot (WB), as well as a commercially available WB developed for serodiagnosing
human AE (Anti-Echinococcus EUROLINE-WB®), using a panel of known status dog sera.
Results: RecEm95-antigen was revealed to be the most promising antigen for use in ELISA, demonstrating
100% (95% CI: 72–100%) sensitivity and 100% (95% CI: 93–100%) specificity in our study. The in-house WB
using EmVF antigen performed as well as the recEm95-ELISA. The commercial WB also correctly identified all
infected dogs, coupled with a specificity of 98% (95% CI: 91–100%).
Conclusion: The recEm95-ELISA alone or in combination with either the in-house WB or the Anti-Echinococcus
EUROLINE-WB® (IgG) with a minor modification should be considered as the best current approach for the serological
diagnosis of dogs infected with the larval stage of E. multilocularis. However, larger studies with a focus on potentially
cross-reacting sera should be undertaken to verify these findings.
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Background
The etiological agent of alveolar echinococcosis (AE) is
Echinococcus multilocularis in its larval (metacestode)
form. Usually, the dog (in addition to the fox and other
wild canids) acts as the definitive host in the life-cycle of
the parasite. Relatively recently, domestic dogs have also
been revealed to be aberrant intermediate hosts for AE
[1]. Although not entailing large numbers of dogs, cases
of canine AE have been regularly reported from Central
Europe since 1988 and from Canada since 2009
(reviewed in [2]). It remains unclear why reports of ca-
nine AE are lacking from other highly endemic regions
such as Central Asia, but possible explanations include
underdiagnosis and reduced susceptibility of dogs to AE
from local strains of the parasite. The most likely route
of infection in dogs is ingestion of E. multilocularis eggs,
either via contaminated food or water or coprophagia.
Some authors have also postulated autoinfection with
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eggs from co-existing adult cestodes in the intestines [3, 4].
Unlike in humans [5], canine AE seems to develop rather
quickly, as reflected by the young median age (3.1 and
4.1 years, respectively, in two unrelated studies) of affected
dogs [6, 7]. Furthermore, AE in dogs is usually diagnosed
only after the parasitic mass has grown to considerable size
and abdominal dilatation is already present [6]; thus the
disease has reached an advanced stage with severe health
impairment. This could be responsible for the relatively
widespread practice of euthanasia without attempting
treatment for AE-affected dogs [6].
Diagnosis of canine AE typically follows initial detec-
tion of suspicious liver lesions on ultrasonographic
examination. Etiological proof of diagnosis is then ascer-
tained by polymerase chain reaction (PCR) or histology
(periodic acid-Schiff staining) on fine needle aspirates or
surgically resected tissues [6]. As these diagnostic ap-
proaches are invasive and most appropriate for rather
advanced AE cases, the availability of non-invasive diag-
nostic techniques might help to yield earlier diagnosis of
AE cases, which in turn favours successful treatment
outcomes. Serology might thus be applied for routine
screening of dogs with a high infection risk (i.e. those
exhibiting coprophagia, hunting rodents or exposed to
foxes and other definitive hosts), when suspicious hep-
atic structures are evidenced by imaging tools, or even
for import screening of dogs travelling to E. multilocu-
laris-free countries. Although most cases of canine AE
are non-fertile as reported by Weiss et al. [8], Peregrine
[9] has discussed the possible implications of importing
a dog with AE to a non-endemic country. Serology for
canine AE has been described by several authors (e.g.
[4]), who used different antigens employed in enzyme-
linked immunosorbent assays (ELISA). In a former
study, we used an Em2-ELISA, in a protocol adapted
from human medicine [6, 10]. For the serodiagnosis of
human AE, the combination of various ELISAs and a
Western blot (WB) is highly recommended as this com-
bination has demonstrated a high diagnostic sensitivity
and specificity [11]. The aim of this study was to search
for the most suitable serological protocol for identifying
metacestode-infected dogs with high sensitivity and spe-
cificity. Commercially available diagnostic kits and re-
combinant antigens were included as these could be
widely applied.
Methods
Dog sera
Group 1: Known-infected dogs (clinical AE cases)
A total of 14 samples were obtained from confirmed
cases of AE. Seven dogs had multiple liver lesions, as ev-
idenced by abdominal ultrasound examination. One dog
had a single lesion that measured about 15 cm in diam-
eter. For the other 6 dogs, this information on the lesion
(s) was unavailable. The disease was diagnosed either by
PCR (13 dogs) or histology (1 dog). All dogs were pri-
vately owned. Serum samples were taken when the dogs
were still alive, at the time of fine-needle aspiration of
the liver lesions. Only one of the dogs was examined for
concurrent intestinal infection with E. multilocularis,
with a negative result on both flotation and copro-
antigen ELISA.
Group 2: Presumed-uninfected dogs
A total of 41 samples were randomly selected from our
serobank. Serum samples were obtained either from the
small animal clinic from healthy blood donors or from
submissions from local veterinarians for the serodiagno-
sis of other parasitic diseases, such as Babesia canis,
Leishmania infantum, Dirofilaria immitis and Neospora
caninum. No information on infection status with E.
multilocularis was available for these dogs.
Group 3: Negative control group
A total of 20 samples were obtained from dogs housed
in a controlled environment (experimental industrial
dog facility at the Novartis Centre de Recherche in St-
Aubin, Switzerland) throughout their life, receiving only
a commercial food. Their health status was monitored
on a daily basis and coprological examination for para-
sites was performed at least once per year, always with
negative results. Serum samples were taken for general
health observations and aliquots were sent to the Insti-
tute of Parasitology in Bern for this study. The dogs
were kept according to Swiss animal welfare regulations.
Parasite antigens and serological methods
Antigens used for ELISA were as follows: E. multilocu-
laris vesicle fluid (EmVF) antigen was produced by in
vitro cultivation and subsequent vesicle fluid collection
as previously described [11]; Em2-antigen was purified
by affinity chromatography as previously described [12];
recombinant Em18-antigen (recEm18) was produced ac-
cording to Xiao et al. [13]; recombinant Em95 (recEm95)
was synthesized according to the method described by
Gauci et al. [14]. The antigen used for in-house WB was
the same EmVF-antigen as that used for ELISA [11].
Coating of 96-well microplates for ELISA was done
with 5 μg/ml EmVF- or with 0.5 μg/ml recombinant
antigen (recEM95, recEM18) in coating buffer (bicar-
bonate/carbonate coating buffer (100 mM, pH 9.6) incu-
bated overnight at 4 °C. Em2-antigen at 0.57 μg/ml
coating buffer was used to coat wells according to Dai et
al. [15]. After coating, plates were washed thrice with
phosphate-buffered saline (PBS)-0.05%-Tween20, and
then blocked with 100 μl per well sample diluent buffer
(PBS-0.05%Tween20 with 0.05% bovine haemoglobin).
Sera diluted 1:100 were added at 100 μl per well. Serum
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was incubated for 30 min at 37 °C. After three washings,
a rabbit anti-dog Immunoglobulin G (IgG)-alkaline
phosphatase conjugate (A0793, Sigma-Aldrich, Buchs,
Switzerland) diluted 1:4000 in sample diluent buffer was
added at 100 μl per well, subsequent incubation was for
30 min at 37 °C. After three washings as described
above, 100 μl substrate solution (p-Nitrophenyl phos-
phate in 1 M diethanolamine, pH 9.8, with 0.5 mM
MgCl2 buffer) was added and incubated for 15 min at
37 °C. The reaction was stopped with 100 μl of 3 M
NaOH (100 μl/well). Plates were read at 405 nm with a
Tecan sunrise ELISA reader using Magellan software
(Tecan, Männedorf, Switzerland).
Western blots
In-house WB
SDS-PAGE resolution of EmVF-antigen and electro-
transfer onto nitrocellulose was performed as previously
described by Müller et al. [11]. WB-strips were incu-
bated with dog sera at a 1:10 dilution in PBS-Tween plus
5% skimmed-milk powder and then incubated overnight
at 4 °C, gently agitated using a mechanical rocker. All
subsequent steps were performed on the rocker. Four
washes for 5 min each with PBS-Tween were then per-
formed. This was followed by incubation with a rabbit
anti-dog-IgG-horseradish-peroxidase conjugate (Sigma,
A6792) at a dilution of 1:200 in PBS-Tween for 2 h at
room temperature (RT). Washing of the nitrocellulose-
strips was done with PBS-Tween (twice), followed by
two washings with PBS only. DAB (one 3,3′-Diamino-
benzidine tetrahydrochloride 10 mg tablet per 20 ml
PBS buffer; Sigma D5905) was added as substrate with
10 μl of H2O2 and incubated for 15 min at RT. After-
wards, the strips were washed three times with distilled
water to stop reactions. For banding pattern interpre-
tation, sera were considered antibody-positive if any of
the 8 kD or 21 kD bands were recognized by the serum.
Of the total 75 samples available, only 72 dog sera were
tested by in-house WB; no serum was left after ELISA
testing for three dogs from group 2.
Anti-Echinococcus EUROLINE-WB® (IgG)
The Anti-Echinococcus EUROLINE-WB® (IgG) is a com-
mercially available immunoblot system for the detection
of antibodies against Echinococcus spp. in human sera.
Antigens of Echinococcus sp., among others the p7 anti-
gen, were electrophoretically separated and transferred to
a membrane that was cut into thin strips. Additionally,
three chips with recombinant antigens recEm18, recEm95,
and recEgAgB were embedded onto each strip. Antibodies
present in serum samples can thus bind to the whole para-
site antigen as well as to the three defined antigens in the
same assay. The test procedure was performed exactly as
recommended by the manufacturer with the exception
that, instead of an anti-human IgG conjugate, a rabbit
anti-dog IgG-alkaline phosphatase conjugate (Sigma,
A0793) diluted 1:200 was used. In brief, one strip per
serum sample was blocked for 15 min with 1.5 ml of the
universal buffer supplied with the kit. Sera were diluted
1:51 in the universal buffer (final volume 1.5 ml) and incu-
bated at RT for 30 min while gently shaking. Then, strips
were washed three times for 5 min with the universal buf-
fer. Rabbit anti-dog IgG-alkaline phosphatase conjugate
(Sigma, A0793) was diluted 1:200 in universal buffer and
1.5 ml were added per strip, followed by 30 min of incuba-
tion at RT, while shaking gently. Washing steps were
repeated as above. Finally, 1.5 ml of the ready-to-use sub-
strate solution contained in the kit was added to each
strip, and the reactions allowed proceeding for 10 min.
Strips were washed three times for 1 min with distilled
water to stop reactions and subsequently analysed using
the EUROLineScan software. Two sera of truly positive
dogs could not be tested in the EUROLINE-WB® because
there was not enough serum left.
ROC analysis
The performance of each ELISA test was assessed by ana-
lysis of the receiver-operating characteristic (ROC) curve
and the area under curve (AUC) [16]. This was done twice
for each test, comparing results for dogs from group 1
(truly positive dogs) with those from dogs from groups 2
and 3 as well as comparing results for dogs from groups 1
and 3 only. The cut-off was chosen based on the point
where the ROC curve was closest to a perfect discrimin-
ation between infected and non-infected dogs. Data ana-
lysis was performed with R software version 3.3.1 [17]
with additional packages ROCR version 1.0–7 [18] and
OptimalCutpoints version 1.1–3 [19].
Results
The best performance on all tested sera (groups 1 to 3)
was obtained with the recEm95 antigen: 100% (95% CI:
72–100%) sensitivity and 100% (95% CI: 93–100%) speci-
ficity (Fig. 1, Table 1). EmVF also had a very high sensi-
tivity (100%; 95% CI: 78–100%), but a lower specificity
of 85% (95% CI: 74–92%). Em2-antigen was able to dis-
tinguish between infected and uninfected dogs with a
sensitivity of 79% (95% CI: 52–92%) and a specificity of
97% (95% CI: 89–99%). RecEm18 achieved the same sen-
sitivity of 79% (95% CI: 52–92%), with the same specifi-
city as EmVF (85%; 95% CI: 74–92%). When only groups
1 (truly positive dogs) and 3 (truly negative dogs) were
compared, cut-off values were identical except that for
recEm18 which was slightly lower (Table 2). Test per-
formance in this comparison improved for recEm18 and
even reached perfect sensitivity and specificity for
EmVF. Performance remained unchanged for recEm95
and the specificity slightly decreased for Em2 (Table 2).
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Both WBs proved to be superior in both sensitivity and
specificity to all ELISAs except the recEm95 ELISA. The
in-house WB correctly identified all infected dogs as sero-
positive and all putatively uninfected and known unin-
fected dogs as seronegative [sensitivity = 100% (95% CI:
77–100%), specificity = 100% (95% CI: 94–100%)]. In de-
tail, 10 sera recognized both bands (Fig. 2), 3 sera recog-
nized the 21 kD band only, and a single serum sample
reacted only with the 8 kD band (Table 3). As the WB was
considered positive if any of the specific bands were recog-
nized, all reactive sera were considered to be positive.
The modified Anti-Echinococcus EUROLINE-WB®
(IgG) also recognized all positive sera as positive with 9
sera reacting with both the recEm95 and the p7 region,
and 3 sera yielding a band only with the recEm95 anti-
gen (Table 3, Fig. 3). In terms of specificity, one sample
from group two (presumably negative dogs) weakly
reacted with the Em95 region of the WB and was inter-
preted as positive by the analysing software. Sensitivity
of the EUROLINE-WB® thus was 100% (95% CI: 74–
100%) and specificity was 98% (95% CI: 91–100%).
Discussion
Serodiagnosis of AE in dogs holds promise as an excel-
lent tool to detect infected dogs at an early stage of in-
fection and/or disease. Late diagnosis of disease often
results in euthanasia or in partial surgical resection with
a high risk of relapse [6]. Use of ELISA as a screening
tool coupled with a confirmatory WB, as is the gold
standard in human medicine [11], might also be an ef-
fective combination for dogs. Ideally, a recombinant
antigen would be preferred for screening purposes, due
to its amenability to large-scale production. In our study,
the recombinant Em95 antigen proved to be very
Fig. 1 Results for all the sera in the different ELISAs. Cut-off values (horizontal lines) were established by ROC-analysis with all groups
Table 1 Performance of each antigen in ELISA when including all
three groups of dog sera. True positive sera (n = 14 of group 1)
were analysed together with true negative sera (group 3)
plus the selected sera from the serobank (group 2). This
scenario yields a realistic impression of routine analysis of
dogs for AE in Switzerland
ELISA AUC Cut-off Sensitivity (95% CI) Specificity (95% CI)
recEm95 1 0.261 1 (0.72–1) 1 (0.93–1)
Em2 0.837 0.430 0.79 (0.52–0.92) 0.97 (0.89–0.99)
EmVF 0.967 0.574 1 (0.78–1) 0.85 (0.74–0.92)
recEm18 0.838 0.329 0.79 (0.52–0.92) 0.85 (0.74–0.92)
Abbreviations: AUC area under curve, CI confidence interval
Table 2 Performance of each antigen in ELISA when including
only known-infected vs known-uninfected dogs. True positive
sera (n = 14 of group 1) were analysed against true negative
sera (group 3) only. This scenario represents an ideal but
unrealistic situation with a clear differentiation between
positive and negative animals
ELISA AUC Cut-off Sensitivity (95% CI) Specificity (95% CI)
recEm95 1 0.261 1 (0.72–1) 1 (0.83–1)
Em2 0.821 0.430 0.79 (0.52–0.92) 0.95 (0.76–0.99)
EmVF 1 0.574 1 (0.78–1) 1 (0.84–1)
recEm18 0.932 0.268 0.86 (0.60–0.96) 1 (0.84–1)
Abbreviations: AUC area under curve, CI confidence interval
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promising both for use in ELISA as well as in the
EUROLINE-WB®. Also EmVF reached perfect sensitivity
(95% CI: 78–100%) in our study, but specificity was
poorer. The other antigens tested, which are used in
screening ELISA’s for the detection of antibodies against
Echinococcus spp. in human medicine, namely the native
antigen Em2, as well as the recombinant Em18 yielded
poorer results compared to those of recEm95. This was
unexpected, since in most other intermediate host species
infected with larval E. multilocularis, conventional anti-
gens including Em2 and recEm18 have demonstrated the
best diagnostic performance so far (reviewed in [20]). Fur-
thermore, both WBs were superior to ELISA’s except for
the recEm95 ELISA. As a stand-alone test or as a con-
firmatory test after screening with ELISA, the Anti-
Echinococcus EUROLINE-WB® (IgG) has the advantage
of being commercially available. However, the test system
has been optimized for humans, and we have exchanged
the conjugate in this study. The kit therefore might not
yet be optimized for application in dogs, based on the one
false positive and some borderline reactions encountered
with the recEm95-antigen, which is blotted onto the WB
strip. Unfortunately, the limited number of serum samples
available did not enable further investigation. Reactions
for sera from group 2 (presumed uninfected dogs) in the
other ELISAs could have been due to infection with the
intestinal stage of E. multilocularis [4] or to exposure to E.
multilocularis eggs that resulted in a seroconversion
against certain antigens, especially the Em2-antigen [21].
Unfortunately, we did not have access to known-status
sera of dogs with intestinal E. multilocularis or other
cestode infections. Sera of such animals were previously
found to cross-react with most antigens used for sero-
diagnosis of canine AE [4] and should be included in fu-
ture studies. Also, we did not have sera from dogs with
other metacestode infections, such as Mesocestoides spp.
or Taenia crassiceps. As well, sera from dogs with non-
parasitic lesions that represent differential diagnoses for
AE should be included in further studies to thoroughly
validate the performance of the recEm95 ELISA as well
as that of the two WBs.
The most exhaustive study to date to identify anti-
gens for serodiagnosis of AE in dogs was carried out by
Staebler et al. [4]. Antigens used by those authors in-
cluded E. multilocularis Em2G11, EmII/3–10 (which
diagnostically matches recEm18), protoscolex (EmP),
excretory/secretory and adult integument (EmAd/I) an-
tigens. Additionally, hydatid fluid (EgHF) and antigen B
(EgAgB)) from E. granulosus were investigated [4]. The
highest sensitivities for AE were obtained by the
EmAd/I and the EmP antigens (97 and 93% sensitivity,
respectively) with high specificities for the control
group of 76 dogs (100 and 98.7%, respectively) [4].
Heterologous E. granulosus antigens (EgHF and EgAgB)
Fig. 2 E. multilocularis Western-blot (in-house) with dog sera. Lanes 1,
3: infected dogs (group 1). Lane 2: known-uninfected dogs (group 3).
Lanes 4, 5: presumably uninfected dogs (group 2)
Table 3 Recognized bands in both WB per group of dog sera
Dog sera group In-housea EUROLINE-WB® (IgG)a
8 kD 21 kD Em95 p7
Infected (group 1) 11/14 13/14 12/12 9/12
Uninfected (group 2) 0/38 0/38 1/41 0/41
Negative control (group 3) 0/20 0/20 0/20 0/20
aIndicated are: sera recognizing the band/all sera tested. When at least one of
the bands was recognized by a serum, the result of the WB was interpreted
as positive
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showed low sensitivities (43 and 50%, respectively) with
high numbers of false positive reactions (> 16%) in the
control group [4]. However, the authors did not include
WB in their study. Based on our experience, WB is the
best performing method, although more laborious com-
pared to ELISA. The most problematic serodiagnosis of
AE we have experienced so far was in AE-affected bea-
vers, whereby only WB was able to reliably diagnose in-
fection [22]. Our finding that the recEm95-antigen,
which was initially designed to vaccinate rodents
against AE [14], also performs well for the detection of
infection in an intermediate host species is new, and
warrants further investigation of its use as a diagnostic
antigen in other intermediate host species. RecEm95 is
a homologue of Eg95, which is a dominant oncospheral
antigen of E. granulosus [23]. In humans, recEm18 is
the antigen of choice for follow-up of patients with AE
[24], i.e. the serological response against this antigen
Fig. 3 Anti-Echinococcus EUROLINE-WB® (IgG) with dog sera. a Serum of an infected dog (group 1). b Serum of an uninfected dog of group 2. The
Anti-Echinococcus EUROLINE-WB® (IgG) is automatically read and interpreted by the EUROLineScan software. Horizontal bars represent intensity of the
respective bands as automatically calculated by the software. Results are o = negative, (+) = borderline or + = positive
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correlates well with active and proliferating, as well as
degenerating, metacestodes. It remains to be seen if
there exists an antigen that will enable similar monitor-
ing of the evolution of the metacestode infections in
treated AE-dogs.
Conclusion
Based on the results for the sera tested in this study, the
recEm95-ELISA alone or in combination with either the
in-house WB or the Anti-Echinococcus EUROLINE-
WB® (IgG) with a minor modification should be consid-
ered the best current approach to the serological diagno-
sis of dogs infected with the larval stage of E.
multilocularis. The advantage of recombinant antigens
and commercially available tests are their broad avail-
ability and applicability to any diagnostic laboratory.
However, more known status sera from dogs with intes-
tinal E. multilocularis infections and from dogs suffering
from other pathologies that constitute differential diag-
noses for AE should be included in further studies to
fully assess the performance of the most promising anti-
gens identified in the present study.
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